Elmiron is a prescription drug used to treat bladder pain or discomfort from interstitial cystitis. Interstitial cystitis is a chronic regional pain syndrome of the bladder and pelvis that predominately affects females, manifesting with urinary urgency and pain or discomfort. More than 1 million people in the United States are estimated to be affected by this condition, which can also disrupt sleep and lead to emotional stress.
Despite its success in treating interstitial cystitis, Elmiron has been like through multiple scientific studies to a specific type of progressive and permanent eye disease called pigmentary maculopathy. The damage caused by Elmiron can sometimes be confused with or initially diagnosed as age-related macular degeneration, macular or pattern dystrophy, diabetic retinopathy, or certain other genetic retinal diseases.
Pigmentary maculopathy eye damage typically results in certain symptoms, including prolonged light to dark adaptation, blurry vision, difficulty reading, metamorphopsia (lines look curvy), central vision loss, loss of vision detail, dimming of vision, blind splits, floaters, spots, impaired color vision, difficulty with near vision, or even blindness.
Lawsuits have been filed by individuals who have developed vision problems after taking Elmiron, claiming the prescription drug manufacturers of manufacturing, marketing, and selling a pharmaceutical which they knew or should have known could cause eye issues, yet did not properly warn consumers, physicians, or the public.
If you or a loved one has experienced any of the symptoms described above after taking Elmiron, contact the experienced dangerous drug attorneys at Neumann Law Group for a free consultation.